Status:
UNKNOWN
Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine
Lead Sponsor:
University Hospital, Bonn
Conditions:
Schizophrenia
Hyperprolactinemia
Eligibility:
MALE
18-60 years
Phase:
PHASE3
Brief Summary
Antipsychotic drugs can cause a clinically relevant hyperprolactinemia due to blocking the dopamine receptors in the pituitary.Schizophrenic patients suffering from a neuroleptic-induced hyperprolacti...
Detailed Description
Antipsychotic drugs can cause a clinically relevant hyperprolactinemia due to blocking the dopamine receptors in the pituitary.Depending on its concentration hyperprolactinemia causes a median hypogon...
Eligibility Criteria
Inclusion
- Female and male schizophrenic patients.
- Antipsychotic treatment with risperidone.
- Diagnosis of a clinically relevant hyperprolactinemia.
- No indication of disturbance of the somato-, cortico or thyreotropic hypophysis-axis (IGF-1, cortisol, ACTH, TSH, FT3, FT4)
Exclusion
- Severe somatic disease, especially coronary disease.
- Acute psychotic exacerbation.
- Pregnancy
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00315081
Start Date
May 1 2006
End Date
May 1 2008
Last Update
April 17 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Bonn, Department of Psychiatry
Bonn, Northrhine-Westfalia, Germany, 53105